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The purpose of this research study was to establish ziprasidone HCl NR 40 mg and trihexyphenidyl 
HCl SR 4mg in the form of bi-layer sustained release floating tablets. The tablets were prepared using 
sodium HPMC K4M / HPMC K15M as bio-adhesive polymers and sodium bicarbonate acting as a 
floating layer. Tablets were evaluated based on different parameters such as thickness, hardness, friability, 
weight variation, in vitro dissolution studies, content of active ingredient and IR studies. The physico-
chemical properties of the finished product complied with the specifications. In vitro release from the 
formulation was studied as per the USP XXIII dissolution procedure. The formulations gave a normal 
release effect followed by sustained release for 12 h which indicates bimodal release of ziprasidone 
HCl from the matrix tablets. The data obtained was fitted to Peppas models. Analysis of n values of 
the Korsmeyer equation indicated that the drug release involved non-diffusional mechanisms. By the 
present study, it can be concluded that bi-layer tablets of ziprasidone HCl and trihexyphenidyl HCl will 
be a useful strategy for extending the metabolism and improving the bioavailability of Ziprasidone HCl 
and Trihexyphenidyl HCl.
Uniterms: Bi-layer tablet. Ziprasidone HCl. Trihexyphenidyl HCl. Sustained release.
O propósito deste trabalho foi preparar ziprasidona. HCl NR 40 mg e triexifenidila.HCl SR 4 mg na forma 
de comprimidos efervescentes bicamada de liberação controlada. Os comprimidos foram preparados 
utilizando HPMC K4M / HPMC K15M sódico como polímero bioadesivo e bicarbonato como camada 
efervescente. Os comprimidos foram avaliados quanto a diferentes parâmetros, como espessura, dureza, 
friabilidade, variação de peso, dissolução in vitro, conteúdo do ingrediente ativo e estudos de IV. As 
propriedades físico-químicas dos produtos finais cumprem as especificações. A liberação in vitro da 
formulação foi estudada de acordo com o procedimento de dissolução da USP XXIII. As formulações 
resultaram em liberação normal, seguida por liberação controlada por 12 h, o que indica a liberação 
bimodal de cloridrato de ziprasidona dos comprimidos matriz. Os dados obtidos se adequaram aos modelos 
de Peppas. A análise de valores de n da equação de Korsmeyer indicou que a liberação do fármaco 
envolveu mecanismos não difusionais. Por este estudo, pode-se concluir que os comprimidos bicamada 
de  ziprasidona.HCl  e de triexifenidila.HCl serão um bom caminho para estender o metabolismo e para 
melhorar a biodisponibilidade de ziprasidona.HCl  e de triexifenidila.HCl.
Unitermos: Comprimidos bicamada. Ziprasidona.HCl. Triexifenidila.HCl. Liberação controlada.
INTRODUCTION
Combination therapy has various advantages over 
monotherapy such as minimization of dose-dependent side 
effects, a low-dose combination of two different agents can 
reduce the dose-related risk, the addition of one agent may 
counteract some deleterious effects of the other, while using 
low dosage of two different agents minimizes the clinical 
and metabolic effects that occur with maximal dosage of 
individual components of the combined tablet. Ziprasidone 
is a one of the potent psychotropic agents that is chemically 
unrelated to phenothiazine or butyrophenone antipsychotic 
agents. Ziprasidone is indicated for the treatment of schi-
zophrenia, bipolar I disorder and acute agitation in schi-
zophrenic patients (www.rxlist.com). Ziprasidone is well 
absorbed after oral administration, reaching peak plasma 
concentrations in 6 to 8 hours. The absolute bioavailabi-
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lity of a 20 mg dose is approximately 60%. Studies show 
that the incidence of reported extra pyramidal side effects 
(which includes the adverse reactions of extrapyramidal 
syndrome, hypertonia, dystonia, dyskinesia, hypokinesia, 
tremor, paralysis and twitching) for ziprasidone-treated 
patients in short-term, placebo-controlled schizophrenia 
trials was 14% vs. 8% for placebo, and the incidence of 
reported extra pyramidal side effects (EPS) (www.thom-
sonhc.com) for ziprasidone-treated patients in short-term, 
placebo-controlled bipolar disorder trials was 31% vs. 12% 
for placebo (Sean et al., 2006) . Thus, there is a need of a 
drug for the treatment of EPS while ziprasidone therapy 
continues being administered. Trihexyphenidyl hydro-
chloride is a synthetic antispasmodic drug  indicated as 
an adjunct in the treatment of all forms of Parkinsonism 
(post-encephalitic, arteriosclerotic, and idiopathic). Addi-
tionally, it is indicated for the control of extrapyramidal 
disorders caused by central nervous system drugs (www.
rxlist.com) such as the dibenzoxazepines, phenothiazines, 
thioxanthenes, and butyrophenones (Anthony et al., 2006). 
The dosage of trihexyphenidyl hydrochloride associated to 
EPS is usually 5 to 15 mg daily in 2 or 3 divided doses. Some 
patients, however, are successfully treated with as little as 1 
mg daily. However, high doses of trihexyphenidyl HCl may 
produce central nervous system manifestations and signs 
that mimic functional psychosis such as hallucinations, 
delusions, agitation, anxiety and paranoia (Porteus et al., 
1956). A common practice when prescribing anti-psychotics 
is the concurrent administration of anticholinergics, either 
to prevent or treat EPS. This addition of anticholinergics to 
patients on antipsychotics, particularly, those with signifi-
cant inherent anticholinergic properties, would theoretically 
increase the risk of anticholinergic side-effects. One of the 
side-effects that is rarely recognized or reported is exacer-
bation of the positive symptoms of schizophrenia, which 
if unrecognized, may cloud the physician’s judgment on 
the patient’s progress (Owens et al., 1999). Combination 
therapy of antipsychotics along with Trihexyphenidyl.HCl 
is important for the adequate control of extrapyramidal side 
effects. Hence, to reduce frequency of administration and 
to improve patient compliance, bilayer tablet formulations 
having a normal disintegration layer (of ziprasidone.HCl) 
and another of a sustained floating release layer (of trihe-
xyphenidyl.HCl) was attempted. The multilayered tablet 
concept has been long utilized to develop sustained release 
formulations. These tablets have a fast releasing layer and 
may contain bi- or triple layers to sustain the drug release 
(Abraham et al., 1997). The pharmacokinetic advantage 
relies on the fact that drug release from normal releasing 
granules leads to a rise in blood concentration. However, 
the blood level is maintained at a steady state as the drug is 
released from the sustaining granules. Among the different 
polymers, HPMC K4M, HPMC K15M have been used 
successfully to obtain appropriate sustained release matrix 
formulations of different materials (Velasco et al., 1999). 
The aim of the present study was to formulate bilayered 
tablets of trihexyphenidyl.HCl SR and ziprasidone.HCl 
with a normal release layer.
EXPERIMENTAL
Materials
Ziprasidone hydrochloride (99.96% purity), HPMC 
K4M, HPMC K15M and microcrystalline cellulose were 
from AET pharmaceuticals, Hyderabad. Trihexyphenidyl 
hydrochloride (99.96% purity) was given by Pharmafabri-
con, Madurai as a gift sample. Sodium bicarbonate [Finer 
chemicals (India) pvt.ltd. Ahmedabad], colloidal silicon 
dioxide [Accord labs. Secunderabad], starch [Karnataka 
fine chem. Bangalore], magnesium stearate and talc [S.D 
fine chem.ltd] were sourced from the local market. All 
other reagents and chemicals used were of analytical 
reagent grade. 
Development of bilayer tablet of trihexyphenidyl.
HCl and ziprasidone.HCl was carried out by the direct 
compression method. Finally it was optimized according 
to several evaluation parameters.
Dose calculation for sustained release layer
The total dose of trihexyphenidyl for a once-daily 
sustained-release formulation was calculated by the follo-
wing equation 
Dt = Dose (1 + 0.693 × t/t1/2)
Where, Dt = total dose of drug; Dose = dose of the 
immediate release part; t = time (hours) during which the 
sustained release is desired; t1/2 = half-life of the drug.
For the normal release layer, the drug dose was 
selected based on the drug profile.
Construction of theoretical release profile
The theoretical release profile of a drug for the sus-
tained release layer was plotted on the basis of the loading 
dose and the drug availability rate. 
Physical characteristic (color) studies for drug-excipients
Preformulation testing entailed an investigation of 
physical and chemical properties of drug substances alone 
and when combined with excipients. It was the first step in 
the rational development of the dosage form. Trihexyphe-
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nidyl.HCl and ziprasidone.HCl alone and mixtures consis-
ting of trihexyphenidyl.HCl with various excipients, and 
ziprasidone.HCl with various excipients at a 1:5 ratio were 
produced and kept at room temperature in a glass vial. This 
was carried out for one month in open and closed glass vials. 
At 2 and 4 week intervals, the samples were withdrawn and 
physical characteristics such as color change, if any, was 
recorded.  Finally, the mixture with no color change was 
selected for formulation (Vijay et al., 2002).
Preparation of bilayer formulation
• Preparation of normal release layer of ziprasidone.HCl:
The immediate release layer of ziprasidone.HCl (Z1 
and Z2) was prepared by the direct compression method 
as per the composition Table I. Ziprasidone HCl, micro-
crystalline cellulose and starch were passed through sieve 
40. All the above were mixed in geometric proportion in a 
poly bag for 15 minutes. Aerosil and magnesium stearate 
were passed through sieve 60 and mixed with above blend 
in a poly bag for 2 minutes.
• Preparation of sustained release layer of trihexyphenidyl. 
HCl:
The dose of trihexyphenidyl.HCl for sustained re-
lease was set at 4 mg using the dose calculation formula. 
The trihexyphenidyl.HCl (T1 to T10) sustained release 
layer was prepared by the direct compression technique 
with various excipients as per the formula given in Table 
II. The drug and additives were passed through sieve 40 
and mixed thoroughly in a poly bag for 30 minutes for 
uniform mixing. Dried mixture materials were passed 
through a milling 1.5 mm screen and sifted through sieve 
20 and finally lubricated with the lubricants.
• Characterization of granules:
Prior to compression, granules were evaluated for 
their characteristic parameters, such as density, bulk den-
sity, tapped density, compressibility index and Hausner 
Ratio. Carr’s compressibility index was calculated from 
the bulk and tapped densities using a digital tap density 
apparatus (Electrolab Ltd, India).
• Preparation of bilayer formulation:
Final bilayer tablets were compressed as one layer 
only for trihexyphenidyl.HCl and with a second layer for 
ziprasidone.HCl using a 19.8x8.7 mm oblong shaped pun-
ch on a 27 station tablet compression machine (Cadmach, 
India) in the following manner F1(T1+Z1), F2(T2+Z1), 
F3(T3+Z1), F4(T4+Z1), F5(T5+Z1), F6(T6+Z1), 
F7(T7+Z1), F8(T8+Z1), F9(T9+Z1), F10(T10+Z1), 
F11(T1+Z2), F12(T2+Z2), F13(T3+Z2), F14(T4+Z2), 
TABLE I - Preparation of normal release layer of ziprasidone.HCl
S. No Ingredient Category (Z1) Quantity/Tablet (in mg) (Z2) Quantity/Tablet (in mg)
1 Ziprasidone.HCl Active ingredient 40 40
2. Microcrystalline cellulose Binder/diluent 52 47
3. Aerosil Glidant 5 10
4. Colloidal Silicon dioxide Adsorbent/ tablet disintegrant 2 2
5 Magnesium stearate Lubricant 1 1
Total composition 100 mg/tablet 100 mg/tablet
TABLE II - Preparation of sustained release layer of trihexyphenidyl.HCl
S.No. Ingredient Category Quantity/Tablet (in mg)
T1 T2 T3 T4 T5 T6 T7 T8 T9 T10
1. Trihexyphenidyl.HCl Active ingredient 4 4 4 4 4 4 4 4 4 4
2. HPMC  K15M Polymer 40 35 30 25 20 - - - - -
3. HPMC K4M Polymer - - - - - 40 35 30 25 20
4. Starch Binder 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5
5. Talc Glidant 1 1 1 1 1 1 1 1 1 1
6. Sodium bicarbonate Effervescent Material 3.5 8.5 13.5 18.5 23.5 3.5 8.5 13.5 18.5 23.5
Average Weight of tablets (mg/tablet) 50 50 50 50 50 50 50 50 50 50
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F15(T5+Z2), F16(T6+Z2), F17(T7+Z2), F18(T8+Z2), 
F19(T9+Z2) and F20(T10+Z2). The tablet was compres-
sed as a bilayer tablet using both Trihexyphenidyl HCl and 
Ziprasidone HCl granules. To achieve this, Trihexypheni-
dyl HCl granules were introduced first into the die cavity 
and a slight pre compression was made so that the layer 
was uniformly distributed. Subsequently, ziprasidone.HCl 
granules were added and a final compression was made. 
• Physical tests for bilayer tablets:
Standard physical tests for the bilayer tablets were 
performed and average values calculated. Mass variation 
was determined by weighing 20 tablets individually, and 
the average mass and percent variation of each tablet was 
calculated. Hardness was determined by taking 6 tablets 
from each formulation using a Monsanto hardness tester 
(Electrolab Pvt. Ltd., India) and the average pressure 
(kg cm–2) applied to crush the tablet was determined. 
Friability was determined by first weighing 20 tablets 
after dusting and then placing them in a Roche Friabilator, 
which was rotated for 4 min at 25 rpm. After dusting, the 
total remaining mass of the tablets was recorded and the 
percent friability calculated. Thickness was determined 
by Digital Vernier Calipers and expressed in mm. (Leon 
Lachmann, et al., 1987)
Drug content uniformity
• Determination of drug content of Ziprasidone HCl:
The standard ziprasidone.HCl (10 µg/mL) was 
prepared using 7.4 pH phosphate buffer with 1% sodium 
lauryl sulphate (SLS). Ten tablets with predetermined wei-
ght from each batch were taken and crushed in a mortar. An 
amount equivalent to 100 mg was weighed and transferred 
to a 100 mL volumetric flask and 7.4 pH phosphate buffer 
with 1%SLS was sonicated for about 20 min to ensure 
complete solubility of the drug. The mixture was made 
up to volume using 7.4 pH phosphate buffer with 1%SLS. 
The solution was suitably diluted and finally 10 µg/mL 
concentrated solutions were prepared. Absorption was 
determined by a UV-Visible spectrophotometer at 316 nm 
for both standard and sample solutions. The content of 
ziprasidone.HCl per tablet in mg was then calculated.
• Determination of drug content of trihexyphenidyl.HCl:
The standard trihexyphenidyl.HCl (10 µg/mL) 
was prepared using 0.1 N hydrochloric acid. Ten ta-
blets with predetermined weight from each batch were 
taken and crushed in a mortar. An amount equivalent to 
100 mg was weighed and transferred to a 100 mL volu-
metric flask and 0.1 N hydrochloric acid was sonicated 
for about 20 min to ensure complete solubility of the 
drug. The mixture was made up to volume using 0.1 N 
hydrochloric acid. The solution was suitably diluted and 
finally 10 µg/mL concentrated solutions were prepared. 
The absorption was determined by a UV-Visible spec-
trophotometer at 250 nm for both standard and sample 
solutions. The content of trihexyphenidyl HCl per tablet 
in mg was then calculated.
In vitro dissolution
• Preparation of stock solutions:
From 100 µg/mL stock ziprasidone.HCl solution, 
2, 4, 6, 8, 10, 12, 14, 16, and 18 µg/mL solutions were 
prepared and absorbance measured at 316 nm using a 
UV spectrophotometer. Finally, a graph was plotted with 
concentration vs absorbance.
From 100 µg/mL stock trihexyphenidyl.HCl so-
lution, 2, 4, 6, 8, 10, 12, 14, 16, and 18 µg/mL solutions 
were prepared and absorbance measured at 250 nm using 
a UV spectrophotometer. Finally, a graph was plotted with 
concentration vs absorbance.
• Procedure for ziprasidone.HCl tablets:
Release of ziprasidone.HCl was determined using 
a Dissolution Apparatus Type II of USP (Paddle) at 50 
rpm. The dissolution was studied using 900 mL of 7.4 pH 
phosphate buffer solution with 1% SLS. The temperature 
was maintained at 37 ± 0.5 °C. The sample (5 mL) was 
withdrawn at different time intervals, i.e., 5, 10, 15, 20, 
25, 30, 35, 40, 45, 50, 55, 60, 75, 90, 105, 120 and 150 
minutes, filtered through Whatman filter paper (Auroco 
Pvt Ltd, Thailand) and replaced by an equal volume of 
dissolution medium. Samples were suitably diluted and 
analyzed for ziprasidone.HCl content using spectrograms. 
The percentage of ziprasidone.HCl release was calculated. 
The solutions were analysed by using same procedure as 
the drug content assay.
• Procedure for trihexyphenidyl.HCl tablets:
Release of trihexyphenidyl.HCl was determined 
using a Dissolution Apparatus II of USP (Paddle) at 50 
rpm. The dissolution was studied using 500 mL of 0.1N 
Hydrochloric acid. The temperature was maintained at 
37 ± 0.5 °C. Samples (5 mL) were withdrawn at diffe-
rent time intervals, i.e. 1, 2, 3, 4, 6, 8, 10 and 12 hours, 
filtered through Whatman filter paper (Auroco Pvt Ltd, 
Thailand) and replaced by an equal volume of dissolution 
medium. Samples were suitably diluted and analyzed for 
trihexyphenidyl.HCl content using spectrograms. The 
percentage of trihexyphenidyl.HCl release was calculated.
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• Dissolution profile comparison using dependent models:
The experimental results of the release studies were 
fitted according to the exponential equation.
Zero order release equation:
Q = K0 t (1)
Higuchi’s square root of time equation:
Q = KH t
1/2  (2)
Korsemeyer-Peppas equation:
F = (Mt/M) = Km t
n  (3)
Where, Q= Amount of drug release at time t, Mt= 
drug release at time t, M= total amount of drug in dosage 
form, F= fraction of drug release at time t, K0= zero order 
release rate constant, KH= Higuchi square root of time re-
lease rate constant, Km= constant dependent on geometry 
of dosage form, n= diffusion exponent indicating the me-
chanism of drug release where cylinder value of n = 0.55 
indicates Fickian diffusion, between 0.45 and 0.89 indicate 
anomalous transport and 0.89 indicates case-II transport.
Similarity factor (f2) was determined between the-
oretical profile value of trihexyphenidyl.HCl and selected 
formulation values. Similarity factor is inversely propor-
tional to the average of squared difference between the 
two profiles, with emphasis on the larger difference among 
all the time points. When the two profiles are identical, 
f2 =100. An average difference of 10% at all measured 
time point’s results in an f2 value of 50. The FDA has 
set a public standard of an f2 value of 50-100 to indicate 
similarity of two dissolution profiles.
FT-IR study
Infrared spectrum was taken (FT-IR, Spectrum RX 
1, Perkin Elmer Ltd, Switzerland) by scanning the sample 
in potassium bromide discs. The samples of pure drug 
and granules containing different polymers were scanned 
individually to find the common bands of the vibrational 
spectra of individual drug and its formulations and also 
to find the differences in the vibrational spectrum of the 
formulation. 
RESULTS AND DISCUSSION
The dose of ziprasidone HCl was 40mg which was 
determined with the help of the drug profile. The total 
dose of trihexyphenidyl for a once-daily sustained-release 
formulation was 4mg,  a value which was calculated by 
equation. Hence, the formulation should release 1 mg in 
1 hour like conventional tablets, and 0.25 mg per hour up 
to 12 hours thereafter. Drug release from planar matrix 
systems has been investigated theoretically with special 
emphasis on the influence of a finite dissolution rate on 
the drug release profile. The mechanism and kinetics of 
the theoretical drug release of trihexyphenidyl was deter-
mined by the application of the Korsmeyer-Peppas model, 
Higuchi’s model, as well as zero order and first order ki-
netics, as shown in Figure 1. The kinetic studies indicate 
that drug release depends on swelling, relaxation and 
erosion of polymer with zero order release kinetics based 
on correlation coefficient (R2) as an indicator of the best 
fit for the theoretical profile considered. The correlation 
coefficient (R2) was 0.9999, 0.7971, 0.9694 and 0.9724 
for zero-order, first-order, Higuchi and Korsmeyer-Peppas 
release models, respectively. 
FIGURE 1 – Dissolution profile for Trihexyphenidyl HCl SR in HCl 0.1 N (each data point represents the mean of 3 units).
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In drug excipient physical characteristic studies, 
the samples which were kept at room temperature, 
withdrawn and evaluated for physical characteristics 
like color change  at different time intervals (days). 
Hence, it can be concluded that all the compositions 
were compatible. 
The preformulation studies of Z1 to Z2 and T1 
to T10 were evaluated for various physical properties 
individually, and values given in Table III. Blend was 
evaluated for bulk density, tapped density, compressibi-
lity index, Hausner ratio and angle of repose. From the 
results shown in Table III, the values of bulk densities 
for the granules of various formulations indicate good 
packing characteristics. The compressibility index (CI) 
for all the formulations was found to be below 15.25%, 
indicating desirable flow properties. The flow properties 
of granules were further analyzed by determining the 
angle of repose for all granules where ranges were less 
than 300. The Hausner ratio for all the granules formula-
ted was less than 1.5 %.
All the batches (F1 to F20) of tablets were produced 
under similar conditions to avoid influence of processing 
variables. The tablets of different formulations were 
subjected to various evaluation tests, such as thickness, 
diameter, uniformity of weight, drug content, hardness, 
friability, buoyancy test and in vitro dissolution. Physical 
evaluation results of all the formulations are shown in 
Table IV. In a weight variation test,  mass values of the 
bilayer tablets were between 148.6 and 152.6mg. The 
average percentage deviation of all tablet formulations 
was found to be within the limit, and hence all formula-
tions passed the test for uniformity of weight as per offi-
cial requirements. The hardness of tablets was between 
6.16 and 8.33 kp and Thickness was 2.5 to 2.76 mm. 
Hardness and thickness studies indicated the strength of 
tablets. The percentage friability of all the formulations 
was between 0.45 and 0.93%. Conventional compressed 
tablets that lose less than 1% of their weight are generally 
considered acceptable. In the present study, the percen-
tage friability for all the formulations was below 1%, 
indicating that their friability was within the prescribed 
limits. Values of the hardness test and percent friability 
indicate good handling properties of the prepared bilayer 
tablets. On the buoyancy test, floating lag time of all ba-
tches was below 30 seconds regardless of viscosity and 
content of HPMC because of evolution of CO2 resulting 
from the interaction between sodium bi carbonate and 
dissolution medium; entrapment of gas inside the hydra-
ted polymeric matrices enables the dosage form to float 
by lowering the density of the matrices. Total floating 
time for the HPMC formulations was below 14hrs. The 
drug content uniformity in the bilayer matrix tablets ran-
ged from 97.39 to 99.94% for ziprasidone hydrochloride 
and 98.54 to 101.39% for trihexyphenidyl hydrochloride. 
From the release profiles it was clear that most of 
the drug of trihexyphenidyl.HCl was released in 0.1 N 
HCl. Approximately 50% of the drug was released within 
5 to 6.2 h for F1, F2, F3, F11, F12 and F13, but for F4, 
F5, F8, F9, F10, F14, F15, F18, F19 and F20 release was 
within 3 to 4 h; for F6, F7, F16 and F17 within 2 to 2.9 
h. Similarly, 90% of the drug release was observed in 
10 to 12 h for F1, F2, F11 and F12; for F3, F4, F13 and 
TABLE III - Characterisation of granules
S.No Formulation Bulk density g/cm3 Tap density g/cm3 Hausner ratio Compressibility  Index (%) Angle of repose(0)
1 Z1 0.453±0.012 0.51±0.024 1.116±0.057 11.02±3.52 28.31±1.429
2 Z2 0.448±0.016 0.518±0.02 1.124±0.045 13.09±1.34 27.95±1.072
3 T1 0.46±0.02 0.515±0.007 1.115±0.02 14.4±1.27 28.25±2.47
4 T2 0.46±0.0 0.54±0.028 1.095±0.04 12±0.7 27.45±0.07
5 T3 0.445±0.03 0.52±0.014 1.105±0.03 10±3.11 29.3±0.98
6 T4 0.45±0.01 0.52±0.014 1.1±0.0 12.45±3.74 27.75±1.48
7 T5 0.45±0.0 0.49±0.014 1.085±0.03 10.85±1.2 29.8±0.28
8 T6 0.455±0.02 0.53±0.028 1.15±0.0 14.1±0.56 27.1±1.69
9 T7 0.45±0.01 0.51±0.014 1.13±0.0 11.75±0.35 27.95±1.62
10 T8 0.45±0.01 0.495±0.035 1.065±0.09 8.9±3.67 26.95±0.35
11 T9 0.45±0.01 0.5±0.028 1.11±0.02 9.9±2.26 29.35±0.91
10 T10 0.44±0.0 0.52±0.028 1.125±0.007 15.25±4.59 28.7±0.56
Z- Ziprasidone.HCl; T – Trihexyphenidyl.HCl Formulation, 
n = 3, mean ± standard deviation
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F14, within 8 to 10 h; for F5, F6, F7, F15, F16 and F17, 
within 6 to 8 h; and for F8, F9, F10, F18, F19 and F20, 
within 4 to 6 h. Thus the concentration of the polymers 
HPMC K4M and HPMC K15M was the predominant 
controlling factor. Formulations F6 to F10 and F16 to 
F20 released the drug completely within 8 h. This was 
ascertained due to the HPMC K4M polymer forming 
a rigid gel barrier around the tablet ultimately leading 
to loss of matrix integrity. Increasing HPMC K15M 
polymer level resulted in sustaining the release for up 
to 11-12hrs. Table V and Figure 1 show the cumulative 
percentage release studies for trihexyphenidyl.HCl SR. 
Based on the results of cumulative drug release profile, it 
was concluded that F1, F2, F11 and F12 were optimized 
formulations in which both F1 and F11 have T1 formula 
and both F2 and F12 have T2 formula. The description 
of dissolution profiles has been attempted using different 
release models. Most of the tablet formulation follows 
zero order release as r2 values are between 0.933 and 
0.991. The correlation coefficient (R2) was used as an 
indicator of the best fit for each of the models conside-
red. The mechanisms of drug release are non-Fickian 
diffusion, since they fitted well with Korsmeyer–Peppas 
models as their r2 values were in the range 0.922–0.994 
with n values above 0.5. This indicates that drug release 
depends on swelling, relaxation and erosion of polymer 
with zero order release kinetics. Table VI depicts the data 
for the correlation co-efficient for all kinetic models of all 
formulations. Similarity factor was calculated between 
selected formulations with a theoretical profile value of 
trihexyphenidyl HCl. Similarity factor value for F1 and 
F11 was 77.9; for F2 and F12 67.2. From this value, it 
was found that formulations F1 and F11 had a release 
profile similar to that of the theoretical release profile 
of trihexyphenidyl.HCl SR. Similarity factor value was 
found to be above 50 and the formulation showed poly-
mer concentration dependent retardation.
Based on the release profiles it was clear that most 
of the ziprasidone.HCl was released in 7.4 pH phosphate 
buffer with 1% SLS. About 50% of the drug was released 
within 50 to 55 min for F1 to F10 and for F11 to F20 
within 55 to 60 min. Similarly, 90% of the drug release 
was observed in 105 to 120 min for F1 to F10 and for F11 
to F20 within 120 to 150 min. Among these formulations 
TABLE IV - Evaluation study for bilayer tablet formulation
Formulation Thick ness
(mm) n=10
Buoyancy test (n=3) Hardness 
(kp) n=6
Friability
(%) n=10
Deviation in weight 
variation (mg) n=20Lag time (sec) Total floating time (h)
F1 2.6 ± 0.1 30.33±0.58 12.33 ±0.58 7.56 ±0.25 0.85±0.02 151.4±3.37
F2 2.63 ± 0.05 23.33±0.58 13.33±0.58 6.16 ±0.23 0.85±0.01 152.2±3.30
F3 2.76 ± 0.11 16.33±0.58 13.33±1.15 6.5 ± 0.34 0.72±0.02 149.5±4.59
F4 2.73 ± 0.15 15.33±2.31 11.33 ±1.15 6.6 ± 0.3 0.66±0.02 151.2±3.57
F5 2.5 ± 0.1 10.00±1.73 11.33 ±1.15 6.7 ± 0.1 0.94±0.02 150.1±4.06
F6 2.7 ± 0.2 26.00±3.46 11.33 ±1.15 7.96±0.32 0.93±0.04 148.9±4.29
F7 2.75±0.05 24.67±1.15 12.57 ±0.58 6.93±0.51 0.67±0.01 150.6±4.30
F8 2.74±1.34 14.33±2.89 13.00 ±1.73 8.33±0.20 0.93±0.04 150.3±4.46
F9 2.64±0.08 14.67±0.58 12.33 ±1.15 7.73±0.32 0.67±0.03 149.8±4.77
F10 2.67±0.06 14.00±1.73 12.00 ±0.00 7.46±0.18 0.94±0.04 150.2±4.18
F11 2.68±0.03 29.33±0.58 10.33 ±0.58 6.6 ± 0.3 0.67±0.03 152.6±2.26
F12 2.76 ± 0.11 22.33±1.15 12.33 ±1.15 7.7±0.14 0.90±0.01 148.6±4.11
F13 2.5 ± 0.1 15.67±1.15 12.57 ±0.58 6.76±0.41 0.90±0.01 150.8±4.48
F14 2.66±0.06 9.67±0.58 13.33 ±0.58 7.4±0.43 0.46±0.01 150.4±3.64
F15 2.71±0.062 26.33±0.58 9.57±0.58 7.1±0.40 0.92±0.02 150.7±2.86
F16 2.67±0.137 27.00±3.46 11.57±0.58 6.63±0.54 0.92±0.04 149.6±3.29
F17 2.65±0.04 15.67±0.58 13.57±1.15 6.16±0.28 0.73±0.01 150.6±3.24
F18 2.6±0.082 12.33±0.58 13.57±1.15 8.33±0.20 0.44±0.02 150.8±4.12
F19 2.68±0.02 24.33±0.58 13.33±0.58 6.5 ± 0.34 0.95±0.03 151.6±4.16
F20 2.64±0.08 10.33±0.58 10.57±1.15 7.7±0.14 0.65±0.02 148.5±3.26
mean ± standard deviation
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F1 to F10 with the Z1 formula showed better dissolution 
properties than F11 to F20 with the Z2 formula. 
Based on the cumulative dissolution studies of 
trihexyphenidyl.HCl and ziprasidone.HCl, similarity 
factor and other physical evaluation studies, the F1 
formulation where T1 and Z1 were present exhibited 
good properties of bilayer tablet formulation in terms of 
excipient proportion. The F1 formulation was therefore 
selected for the further studies.
The FT-IR spectrum of the bilayer tablet ziprasi-
done.HCl, trihexyphenidyl.HCl and F1 formulation are 
shown in Figures 2, 3 and 4, respectively. For ziprasido-
TABLE V - Data for cumulative % release study for trihexyphenidyl.HCl SR
Time
(hr)
Theoretical 
value
F1 & F11 F2 & F12 F3 & F13 F4 & F14 F5 & F15 F6 & F16 F7 & F17 F8 & F18 F9 & F19 F10 & F20
0 0 0 0 0 0 0 0 0 0 0 0
1 25 24.26 ± 
0.96
26.26 ± 
0.96
19.2 ± 
0.91
17.2 ± 
0.93
14.8 ± 
0.74
18.5 ± 
0.52
19.4 ± 
0.43
20.6 ± 
0.70
20.9 ± 
1.08
23.7 ± 
0.7
2 31.25 32.45 ± 
0.65
31.25 ± 
0.40
27.2 ± 
1.23
26.8 ± 
0.78
27.5 ± 
1.05
32.8 ± 
0.85
38.9 ± 
1
30.2 ± 
0.95
32.2 ± 
0.95
35.9 ± 
1
3 37.5 36.25 ± 
0.22
34.25 ± 
0.93
38.11 ± 
0.57
41.1 ± 
0.94
32.8 ± 
1.05
57.2 ± 
0.69
54.2 ± 
0.51
42.8 ± 
0.90
38.9 ± 
1.05
57.2 ± 
0.3
4 43.75 44.76 ± 
0.22
46.75 ± 
1.01
43.11 ± 
0.53
52.6 ±
 0.23
54.2 ± 
0.95
69.4 ± 
0.62
72.4 ± 
0.78
57.2 ± 
0.95
60.2 ± 
0.78
72.4 ± 
1.15
6 56.25 56.24 ± 
0.07
48.27 ± 
1.56
55.21 ± 
0.78
66.2 ± 
0.83
72.4 ± 
0.78
82.6 ± 
0.62
83.5 ± 
0.87
97.2 ± 
1
96.6 ± 
1.24
98.1 ± 
0.95
8 68.75 69.72 ± 
0.19
72.71 ± 
0.58
78.52 ± 
0.47
81.2 ± 
1.74
94.6 ± 
0.60
98.1 ± 
0.72
96.7 ± 
0.55
10 81.25 75.24 ± 
0.12
87.28 ± 
0.28
96.1 ± 
0.73
97.5 ± 
0.65
12 94.86 98.26 ± 
0.22
99.26 ± 
0.72
TABLE VI - Data for correlation coefficient for all formulations
Formulation
R2 Peppas
(n)Zero First Higuchi Peppas
F 1 & F11 0.971 0.797 0.969 0.972 0.661
F2 & F12 0.961 0.749 0.959 0.922 0.656
F3 & F13 0.983 0.834 0.958 0.981 0.751
F4 & F14 0.978 0.856 0.993 0.994 0.767
F5 & F15 0.991 0.892 0.971 0.985 0.842
F6 & F16 0.943 0.906 0.979 0.989 0.703
F7 & F17 0.933 0.951 0.981 0.971 0.665
F8 & F18 0.985 0.806 0.921 0.963 0.733
F9 & F19 0.981 0.820 0.914 0.950 0.724
F10 & F20 0.988 0.873 0.984 0.988 0.645
ne.HCl, FTIR Spectra wave numbers were 3357 cm-1 (for 
NH stretching), 3196 cm-1 (for Aromatic C-H stretch), 
2930 cm-1 (for C-H stretch), 1714 cm-1 (for C=O stretch), 
1631 cm-1 (for C=N stretch),1493 cm-1 (for C-H bending), 
972 cm-1 (for C-N ), 744 cm-1 (for C-H bending) and 651 
cm-1 (for C-H bending). For trihexyphenidyl.HCl, FTIR 
Spectra wave numbers were 3303 cm-1 (for OH stre-
tching), 3023 cm-1 (for Aromatic C-H stretch), 2931 cm-1 
(for C-H stretch), 1446 cm-1 (for C=C stretch), 1394 cm-1 
(for CH2 bending), 936cm-1 (for C-N ) and 700 cm-1 (for 
C-H bending). The wavenumbers of individual drug 
were compared with F1 (combination of Z1 and T1) 
formulated product IR spectrum. For the F1 formulation, 
FTIR Spectra wave numbers were 3303 cm-1 (for NH or 
OH stretching), 3199 cm-1 (for Aromatic C-H stretch), 
2931 cm-1 (for C-H stretch),  1713 cm-1 (for C=O stre-
tch), 1630 cm-1 (for C=N stretch), 1493 cm-1(for C-H or 
C=C), 971cm-1 (for C-N ) and 744cm-1(for C-H bending). 
These results revealed that there was no disturbance in 
the principle peaks of pure drug ziprasidone.HCl and 
trihexyphenidyl.HCl. This further confirms the integrity 
of pure drugs and their compatibility with the excipients.
CONCLUSION
The present research was carried out to develop a 
bilayer tablet of trihexyphenidyl hydrochloride and zipra-
sidone.HCl using disintegrant Colloidal Silicon dioxide 
for the normal release layer and both HPMC K4M and 
Formulation and evaluation of bi-layer floating tablets of Ziprasidone HCl and Trihexyphenidyl HCl 553
HPMC K15M for the sustained release layer. Bilayer ta-
blets showed the appropriate release effect to provide the 
loading dose of the drug, followed by sustained release for 
12 h, indicating promising potential of the trihexyphenidyl 
hydrochloride and ziprasidone hydrochloride bilayer tablet 
as an alternative to the conventional dosage form.
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